On this page ▾
Key takeaways
- An early trial reported improved hearing in all ten people aged 1 to 24 with OTOF-related deafness.
- Hearing improved but did not return to normal, and the therapy is still experimental.
- The treatment delivers a working copy of the OTOF gene into the inner ear.
- Children aged 5 to 8 responded best, and no serious side effects were reported at 6 to 12 months.
An early clinical trial in China reported that gene therapy improved hearing in all ten people aged 1 to 24 who had deafness caused by OTOF gene mutations. Hearing did not return to normal, and the treatment is still experimental1,2. OTOF is short for otoferlin, a protein involved in the conversion of sound into the electrical signals of hearing.
Cochlear implants are an effective option for this kind of deafness, but they require surgery and do not fully replicate natural hearing3. This approach instead targets the root genetic cause.
How does the gene therapy work?
The breakthrough centres on OTOF-related deafness, a rare inherited disorder caused by mutations in the OTOF gene.
This gene is responsible for producing otoferlin, a protein essential for converting sound vibrations into electrical signals that travel to the brain. Individuals with OTOF mutations have structurally intact ears, but their ability to transmit sound is impaired.
In the trial, scientists delivered a working copy of the OTOF gene directly into the inner ear using a modified adeno-associated virus (AAV) vector. Once inside the sensory hair cells, the gene instructs the body to produce otoferlin again, so the sound signal chain can work again.
What did the trial find?
In a trial of 10 participants aged 1 to 24, hearing improved in every participant within a month. By six months, the average level of sound that people could detect had improved from about 106 decibels (dB) to about 52 dB1,2. That is a clear gain, but it is still a hearing loss. Children aged 5 to 8 responded most strongly.
The researchers described the therapy as safe and well tolerated, with no serious adverse events reported in the first 6 to 12 months of follow-up. Longer follow-up is planned1,2.
Teenagers and adults in the trial improved too, which suggests the hearing system may still respond to treatment after early childhood. The trial was small and had no comparison group, so larger studies are needed. If your family lives with this kind of deafness, the results are real progress, even if they are still early.
Global momentum and ethical questions
Trials in China and the United States have also reported hearing improvements in young children with OTOF mutations. These therapies are still being tested, and none is yet routine care. You can read about an earlier safety trial and gene therapy for children born with profound deafness.
Yet as results accumulate, so do ethical questions. Some in the deaf community argue that interventions risk undermining Deaf culture and identity. These discussions are ongoing and will likely grow as the therapies move toward broader clinical use.
Future gene editing
In parallel, researchers are exploring gene editing techniques such as CRISPR-Cas9. Animal studies have shown promise in correcting hearing loss caused by other mutations, though safety concerns around off-target effects must be resolved before human trials.
“Gene therapy is showing real promise for some rare inherited forms of deafness,” said Jessica Tovey, a Clinical Audiologist at Hearology. “As the field progresses, continued trials, early diagnosis and careful ethical engagement will be essential. For now, though, we should applaud the researchers’ pioneering work.”
If you are worried about your hearing or your child’s, a hearing test is the first step.

Frequently asked questions
Can congenital deafness be cured?
Is there a cure for deafness?
What is OTOF-related deafness?
Is gene therapy for deafness available in the UK?
What treatments for deafness are available now?
References:
- [1] J. Qi et al., "AAV gene therapy for autosomal recessive deafness 9: a single-arm trial," Nature Medicine, Jul. 2, 2025, doi: 10.1038/s41591-025-03773-w. [Online]. Available:
- [2] Karolinska Institutet, "Gene therapy restored hearing in deaf patients," news release, Jul. 2, 2025. Accessed: Nov. 16, 2026. [Online]. Available:
- [3] NHS, "Hearing loss," NHS website. Accessed: Nov. 16, 2026. [Online]. Available:
